Please note that this conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. All podium presentation sessions will be recorded and made available as an on-demand program after the conference. All presentations are scheduled to be live, in-person presentations at the date and time (U.S. ET) specified in the program. Poster presentations will not be available for viewing on-demand.

Program in progress.

*-Short talk from proffered abstract

Saturday, October 25

• Plenary Session 5: Artificial Intelligence in Drug Development
• Plenary Session 6: Novel Epigenetic Targets
• Spotlight on Proffered Papers 3
• Concurrent Session 7-9
  • Novel Endpoints
  • Pediatric and Rare Cancers
  • Targeting RNA with Small Molecules

Continental Breakfast

7-8 a.m | Ballroom Foyer and Bolyston Street Hallway.

Plenary Session 5: Artificial Intelligence in Drug Development

8-9:40 a.m. | Level 3, Ballroom AB

Session Cochairs: Vivek Subbiah, Sarah Cannon Research Institute, Nashville, Tennessee

• 8:05 a.m. | Blueprints for the future: AI-guided precision oncology trials
  Vivek Subbiah
• 8:30 a.m.
  Regina Barzilay
• 8:55 a.m.
  Siraj Ali, Lunit, Boston, Massachusetts
• 9:20 a.m. | Panel Discussion

Break

9:40-10 a.m.

Plenary Session 6: Novel Epigenetic Targets

10-11:40 a.m. | Level 3, Ballroom AB

Session Chair: Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, Maryland

• 10:05 a.m.
  Stephen B. Baylin
• 10:28 a.m. | Novel epigenetic targets in leukemia
  Irmela Jeremais, Helmholtz Center, Munich, Germany
• 10:51 a.m. | DNA replication and cell identity
  Constance Alabert, University of Dundee, Dundee, Scotland
• 11:14 a.m. | PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2−breast cancer*
  Shikhar Sharma, Pfizer, San Diego, California
• 11:24 a.m. | Panel Discussion / Q&A

Spotlight on Proffered Papers 3

11:45 a.m.-12:15 p.m. | Level 3, Ballroom AB

Session Chair: Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain

• 11:45 a.m. | Discovery and characterization of a highly potent and orally available SMARCA2 PROTAC degrader*
  Haiyan Ying, Abbisko Therapeutics, Shanghai, China
• 11:55 a.m. | Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window*
  Archie Tse, Adlai Nortye Ltd., Hangzhou, China
• 12:05 p.m. | A STAT3 PROTAC degrader SD-1240: The structure-based design, the structure mechanism of potency and selectivity, and the mechanism of action of anti-tumor activity*
  Haibin Zhou, University of Michigan, Ann Arbor, Michigan

Exhibit Show

12-4 p.m. | Level 2, Exhibit Hall D

Poster Session C

12:30-4 p.m. | Level 2, Exhibit Hall D

Concurrent Sessions 7-9

4:15-5:55 p.m.

Concurrent Session 7: Novel Endpoints

Level 3, Ballroom AB

Session Chair: Philippe L. Bedard, University Health Network, Toronto, ON, Canada

• 4:15 p.m. | ctDNA/MRD guided endpoints
  Philippe L. Bedard
• 4:45 p.m. | Capturing the patient voice: Integrating PROs into early phase oncology trials
  Christina Yap, Institute for Cancer Research, London, England
• 5:10 p.m. | PET imaging endpoints in phase 1/2 clinical trials
  Shadi Abdar Esfahani, Massschusetts General Hospital, Boston, Massachusetts
• 5:35 p.m. | Panel Discussion / Q&A

Concurrent Session 8: Pediatric and Rare Cancers

Level 3, Rooms 302/304

Session Cochairs: Mariella G. Filbin, Dana-Farber Cancer Institute, Boston, Massachusetts and Rodrigo de Almeida Toledo, Vall d’Hebron Institute of Technology, Barcelona, Spain

• 4:20 p.m. | Targeting developmental programs in pediatric high-grade glioma
  Mariella G. Filbin
• 4:45 p.m. | Accelerating breakthroughs in rare cancer treatment through academic–industry partnerships
  Rodrigo de Almeida Toledo
• 5:10 p.m. | Decoding neuroendocrine tumour heterogeneity through AI-driven clinical phenotypes and multiomics integration
  Anguraj Sadanadam, The Institute of Cancer Research, London, United Kingdom
• 5:35 p.m. | Zenocutuzumab efficacy and safety in advanced NRG1+ cholangiocarcinoma: Analysis from the phase 2 eNRGy trial*
  Alison Schram, Memorial Sloan Kettering Cancer Center, Scarsdale, New York
• 5:45 p.m. | Panel Discussion / Q&A

Concurrent Session 9: Targeting RNA with Small Molecules

Level 3, Ballroom C

Session Cochairs: Christopher J. Bowden, Remix Therapeutics, Watertown, Massachusetts and Chris Burge, Massachusetts Institute of Technology, Cambridge, Massachusetts

• 4:20 p.m. | REM-422, a first-in-class mRNA degrader of the MYB oncogene
  Charles Kung, Remix Therapeutics, Watertown, Massachusetts
• 4:45 p.m. | Novel oncology targets for tumors with genomic instability
  Serena J. Silver, Accent Therapeutics, Lexington, Massachusetts
• 5:10 p.m.
  Chris Burge
• 5:35 p.m. | Panel Discussion / Q&A